Skip to main content

Table 1 Clinicopathological and genetic characteristics of AA CRC cases

From: Impact of BRAF, MLH1 on the incidence of microsatellite instability high colorectal cancer in populations based study

 

African Americans

    
 

All

non-MSI-H

MSI-H

Odds Ratio (95% CI)

P

Number of patients

95

66 (69)a

29 (31)a

  

Mean Age

65.7+15.0

-

65.2+14.0

-

65.9+17.5

-

 

0.84

Gender

    

0.39

   Female

56 (59)

37 (57)

19 (66)

1

 

   Male

39 (41)

29 (43)

10 (34)

0.67(0.27–1.67)

 

Site

    

0.47

   Distal

38 (40)

28 (43)

10 (34)

1

 

   Proximal

57 (60)

38 (57)

19 (66)

0.71(0.29–1.77)

 

Mucin Production

95

   

0.15

   None

68 (72)

51(77)

17(58)

1

 

   < 50%

15 (15)

9 (14)

6 (21)

2.0(0.62–6.44)

 

   > 50%

12 (13)

6 (9)

6(21)

3.0(0.85–10.55)

 

Differentiation

90

   

0.47

   Well

3 (3)

2 (3)

1 (3)

1

 

   Moderate

71 (79)

51 (83)

20 (72)

0.64(0.5–8.62)

 

   Poor

16 (18)

9 (14)

7 (25)

0.5(0.17–1.54)

 

Stage

92

   

0.59

   Stage 1

8 (9)

7 (11)

1 (3)

1

 

   Stage 2

37 (40)

24 (38)

13 (45)

0.67(0.09–4.93)

 

   Stage 3

35 (38)

23 (37)

12 (41)

1.08(0.27–4.29)

 

   Stage 4

12 (13)

9 (14)

3 (11)

0.8(0.2–3.27)

 

BRAF

82

   

0.00

   wild type

74 (90)

59 (98)

15 (68)

  

   V600E

8 (10)

1 (2)

7 (32)

27.5(3.1–241.3)

 

hMLH1 methylation (MSP)

70

   

0.33

   Unmethylation

4 (6)

2 (4)

2 (10)

1

 

   Methylation

66 (94)

48 (96)

18 (90)

0.38(0.5–2.87)

 

p16 methylation (MSP)

47

   

0.37

   Unmethylation

28 (60)

14 (54)

14 (67)

1

 

   Methylation

19 (40)

12 (46)

7 (33)

0.58(0.18–1.92)

 

hMLH1 expression by IHC

76

   

0.00

   Normal

50 (65)

45 (83)

5 (23)

1

 

   Negative

26 (35)

9 (17)

17 (77)

16.67(5–50)

 

hMSH2 expression by IHC

74

   

0.29

   Normal

66 (89)

46 (87)

20 (95)

1

 

   Negative

8 (11)

7 (13)

1 (5)

0.33(0.04–2.86)

Â